Articles tagged "Bone marrow transplantation"

2017 American Transplant Congress
Targeting JAK-STAT Pathways with Tofacitinib Provides a Novel Approach for Conditioning in Allogeneic BMT Recipients.
H. Xu, A. Merchak, M. Xu, C. Mort, T. Dowling, L. Kahn, M. Binion, A. Chhabra, Y. Wen, Y. Huang, S. Ildstad.
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
Hematopoietic chimerism achieved by bone marrow transplantation (BMT) induces donor-specific tolerance to solid organ grafts. We previously demonstrated that by targeting recipient immune cells (T,…
2017 American Transplant Congress
Results of Stem Cell and Renal Transplantation in Patients with End Stage Renal Disease After Plasma Cell Dyscrasias.
C. Moliz,¹ B. Redondo,¹ M. Molina,¹ E. Morales,¹ E. Gonzalez,¹ J. Cabrera,² A. Andres.¹
¹Nephrology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; ²Nephrology Department, Hospital Evangelico y Hospital Militar, Montevideo, Uruguay
Introduction: Plasma cell dyscrasias (PCD) are a cause of end stage renal disease (ESRD). Traditionally, renal transplantation (RT) has been avoided in these patients due…
2017 American Transplant Congress
Combination Therapy of iNKT Cell Ligand and CD40-CD154 Signal Blockade Establishes Islet Allograft Tolerance in Non-Myeloablative Bone Marrow Transplant Recipients.
T. Kanzawa,¹ T. Hirai,¹ R. Ishii,¹ M. Okumi,¹ H. Ishida,¹ Y. Ishii,² K. Tanabe.¹
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Cluster for Industry Partnerships (CIP), RIKEN, Tokyo, Japan
Background: Allogeneic islet transplantation is an effective therapeutic option for type 1 diabetes. Toxicity associated with chronic use of immunosuppressants still remains an obstacle for…
2017 American Transplant Congress
Two Months Delayed Induction of Mixed Chimerism After Heart and Kidney Cotransplantation in Nonhuman Primates.
K. Huh,¹ W. Sommer,¹ K. Robinson,¹ X. Wu,¹ J. Paster,¹ I. Hanekamp,¹ A. Dehnadi,¹ T. Kawai,^1,2 R. Smith,³ R. Colvin,^1,3 G. Benichou,¹ J. Madsen.^1,4
¹Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA; ²Department of Surgery, Massachusetts General Hospital, Boston, MA; ³Department of Pathology, Massachusetts General Hospital, Boston, MA; ⁴Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA
Background We have previously achieved transplant tolerance in cynomolgus recipients cotransplanted with heart and kidney by treating recipients with standard triple drug immunosuppression for 4…
2017 American Transplant Congress
Induction of Durable Mixed Hematopoietic Chimerism and Immune Tolerance in Non-Human Primates.
P. Alonso-Guallart,¹ R. Duran-Struuck,¹ J. Stern,¹ S. Kofman,¹ M. Danton,¹ J. Zitsman,¹ Y. Kato,¹ E. Berglund,¹ H. Sondermeijer,¹ A. McMurchy,² M. Levings,² M. Sykes,¹ A. Griesemer.¹
¹Columbia Center for Translational Immunology, Columbia University, New York, NY; ²University of British Columbia, Vancouver, Canada
Mixed hematopoietic chimerism is a promising approach to achieving transplantation tolerance. Transient mixed chimerism leads to renal allograft tolerance in about 70% of cynomolgus macaques…
2017 American Transplant Congress
The Intragraft Vascularized Bone Marrow Component and Recipient T Regulatory Cells Facilitate Tolerance Induction After Post Transplant High Dose Cyclophosphamide Treatment in VCA.
G. Furtmüller, B. Oh, M. Fryer, S. Ganguly, V. Malek, X. Zhou, J. Dodd-o, G. Raimondi, D. Cooney, C. Brayton, W. Lee, L. Luznik, G. Brandacher.
Johns Hopkins University School of Medicine, Baltimore, MD
Background: VCA is a viable treatment option for devastating tissue defects. However, the life-long need for immunosuppression curtails the wider use of VCA. Unique VCA-features…
2017 American Transplant Congress
CD19⁺CD38^hiCD24^hi Immature Transitional B Cells in PBMCs of Tolerant Kidney Recipients of Facilitating Cell-Enriched Hematopoietic Stem Cells and Renal Allografts.
Y. Wen,¹ A. Merchak,¹ Y. Huang,¹ H. Xu,¹ L. Kahn,¹ J. Leventhal,² S. Ildstad.¹
¹Institute for Cellular Therapeutics, University of Louisville, Louisville, KY; ²Comprehensive Transplant Center, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL
CD19+CD38hiCD24hi immature transitional B cells may represent a biomarker for transplantation tolerance in kidney transplant (KTx) recipients (Cherukuri A, et al. J Am Soc Nephrol.…
2017 American Transplant Congress
Depletion of T-Cells from G-CSF Mobilized Human PBMC Prevents Acute GVHD in NSG Mice.
Y. Huang, H. Xu, A. Merchak, A. Chhabra, Y. Wen, L. Kahn, S. Ildstad.
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
Allogeneic HSC transplantation is commonly utilized for the treatment of hematologic malignancies and autoimmune diseases. However, allogeneic HSC transplantation is limited by potential for the…
2017 American Transplant Congress
Dominant Role of Clonal Deletion in Achieving Immune Tolerance After Unrelated Cord Blood Transplantation.
P. Szabolcs,^1,2 X. Chen,¹ M. Hill.¹
¹BMT and Cell Therapy, Children Hospital of Pittsburgh UPMC, Pittsburgh, PA; ²Immunology, University of Pittsburgh, Pittsburgh, PA
The mechanism of immune tolerance after successful hematopoietic stem cell transplantation is not fully understood. Both central (clonal deletion) and peripheral (anergy, Treg, Tr1) mechanisms…
2017 American Transplant Congress
Mouse FCs May Contain Lymphoid Progenitor Cells That Have the Capacity to Generate B and T Cells In Vivo.
A. Chhabra, Y. Wen, Y. Huang, H. Xu, A. Merchak, S. Ildstad.
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
CD8+/TCR- facilitating cells (FCs) are a rare bone marrow-derived cell population that enhances engraftment of hematopoietic stem cells (HSC) in major histocompatibility complex disparate recipients…